Study: GSK candidate malaria vaccine has low efficacy, causes meningitis

Study: GSK candidate malaria vaccine has low efficacy, causes meningitis

https://birdflu666.wordpress.com/2015/10/24/study-gsk-candidate-malaria-vaccine-has-low-efficacy-causes-meningities/

A GSK candidate malaria vaccine funded by the Bill and Melinda Gates foundation has a low efficacy rate and causes meningitis and cerebral malaria, a study shows.

From Cidrap:

World Health Organization (WHO) experts today urged further trials of GSK’s candidate malaria vaccine on the heels of a New England Journal of Medicine (NEJM) study showing that its low efficacy in young children is likely due to a mismatch with the strains of malaria parasite commonly found in Africa.

Results of phase 3 trials involving 15,000 kids published in April showed that four doses of the RTS,S candidate vaccine (Mosquirix)—the world’s first to be tested in humans—had just 36% effectiveness in children 5 to 17 months of age and 26% in infants.


One challenge of implementing the vaccine is whether immunization successes in the phase 3 trials could be replicated in real-life situations because of the four-dose regimen that would require multiple healthcare visits, the experts noted in their recommendations.

They also said the vaccine’s effect on death rates could not be determined from the phase 3 trial, and that the most concerning adverse events—meningitis and cerebral malaria—warrant further exploration.

http://www.cidrap.umn.edu/news-perspective/2015/10/who-experts-urge-gradual-rollout-malaria-vaccine

http://www.nejm.org/doi/full/10.1056/NEJMoa1505819

http://www.malariavaccine.org/files/MVI-GSK-RTSSfactsheetFINAL-web.pdf

Leave a Reply